BBIO — BRIDGEBIO PHARMA INC

Ownership history in Kohlberg Kravis Roberts & Co. L.P.  ·  27 quarters on record

This page tracks every 13F SEC filing in which Kohlberg Kravis Roberts & Co. L.P. reported a position in BRIDGEBIO PHARMA INC (BBIO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
37.06% (2023 Q4)
Avg. % of fund
12.33%
First filed
2019 Q2
Last filed
2025 Q4
Quarters held
27
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 13,260,971 — 0% 16.22% $1.01B $76.49
2025 Q3 UNCHANGED 13,260,971 — 0% 11.54% $688.77B $51.94
2025 Q2 REDUCED 13,260,971 -6,000,000 -31.2% 11.83% $572.61B $43.18
2025 Q1 REDUCED 19,260,971 -6,000,000 -23.8% 15.04% $665.85B $34.57
23 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    BBIO price (monthly, adj. close)

Other funds also holding BBIO

As of 2025 Q4 — sorted by position size

Aisling Capital Management LP 3Y 7Y 81.29% Frazier Life Sciences Management, L.P. 3Y 7.28% First Turn Management, LLC 5.2% BOONE CAPITAL MANAGEMENT LLC 3Y 4.44% Eagle Health Investments LP 3Y 4.36% Monashee Investment Management LLC 3Y 7Y 4.31% Cormorant Asset Management, LP 3Y 7Y 4.24% Atle Fund Management AB 3Y 7Y 3.45% Laurion Capital Management LP 3Y 7Y 3.28% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 3.25%
← Back to Kohlberg Kravis Roberts & Co. L.P. Holdings